- Home
- WHWK vs IMUX Comparison
WHWK vs IMUX Comparison
Compare WHWK & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHWK
- IMUX
- Stock Information
- Founded
- WHWK 2007
- IMUX 2016
- Country
- WHWK United States
- IMUX United States
- Employees
- WHWK N/A
- IMUX N/A
- Industry
- WHWK Biotechnology: Pharmaceutical Preparations
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- WHWK Health Care
- IMUX Health Care
- Exchange
- WHWK Nasdaq
- IMUX Nasdaq
- Market Cap
- WHWK 82.4M
- IMUX 90.4M
- IPO Year
- WHWK N/A
- IMUX N/A
- Fundamental
- Price
- WHWK $1.82
- IMUX $0.76
- Analyst Decision
- WHWK
- IMUX Strong Buy
- Analyst Count
- WHWK 0
- IMUX 5
- Target Price
- WHWK N/A
- IMUX $7.50
- AVG Volume (30 Days)
- WHWK 117.1K
- IMUX 1.3M
- Earning Date
- WHWK 08-07-2025
- IMUX 11-06-2025
- Dividend Yield
- WHWK N/A
- IMUX N/A
- EPS Growth
- WHWK N/A
- IMUX N/A
- EPS
- WHWK N/A
- IMUX N/A
- Revenue
- WHWK $21,596,000.00
- IMUX N/A
- Revenue This Year
- WHWK N/A
- IMUX N/A
- Revenue Next Year
- WHWK N/A
- IMUX N/A
- P/E Ratio
- WHWK N/A
- IMUX N/A
- Revenue Growth
- WHWK N/A
- IMUX N/A
- 52 Week Low
- WHWK $1.39
- IMUX $0.56
- 52 Week High
- WHWK $3.81
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- WHWK 55.63
- IMUX 35.74
- Support Level
- WHWK $1.76
- IMUX $0.85
- Resistance Level
- WHWK $1.87
- IMUX $0.96
- Average True Range (ATR)
- WHWK 0.07
- IMUX 0.06
- MACD
- WHWK 0.02
- IMUX -0.02
- Stochastic Oscillator
- WHWK 83.33
- IMUX 8.50
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.